Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
-
Viking Therapeutic (VKTX) PT Raised to $15 at Maxim Group
-
Pre-Open Movers 07/16: (VTVT) (APRN) (JBHT) Higher; (TNXP) (LEA) (DPZ) (more...)
-
Maxim Group Reiterates Buy Rating, $20 PT on Viking Therapeutic (VKTX)
-
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
-
Viking Therapeutics (VKTX) Prices 9.5M Share Offering at $18.50/Sh
-
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock
-
Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group
-
Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock
-
Viking Therapeutics (VKTX) Prices 7.5M Common Stock Offering at $9/Share
-
Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock
-
UPDATE: Viking Therapeutic (VKTX) PT Raised to $14 at Maxim Group; 'What's Good for Madrigal is Good for Viking'
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock
-
Viking Therapeutics (VKTX) Prices 11M Shares at $5
-
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock
-
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh
-
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock
-
Viking Therapeutic (VKTX) PT Raised to $8 at Maxim Group
-
Viking Therapeutics (VKTX) Enters Purchase Agreements for up to $16.25M with Lincoln Park Capital
-
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital
-
Viking Therapeutics (VKTX) Enters $4.3M Registered Direct Offering
-
Viking Therapeutics Announces $4.3 Million Registered Direct Offering
-
Viking Therapeutics to Present at Upcoming Investor Conferences
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Maxim Group Starts Viking Therapeutic (VKTX) at Buy
-
Viking Therapeutics Announces Full Exercise of Over-Allotment Option
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants
-
Viking Therapeutics (VKTX) Prices Common Stock and Warrant Offering for Proceeds of $9.38M
-
Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants